Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $99.4 million and completed approximately 244,000 Cologuard tests during the year ended Dec. 31, 2016. Full-year 2016 revenues and Cologuard test volume grew 152 percent and 135 percent from 2015, respectively.
During the fourth quarter of 2016, the company generated revenues of $35.2 million and completed approximately 82,000 Cologuard tests. Fourth-quarter 2016 revenues and test volume grew 144 percent and 114 percent from the same period of 2015, respectively.
“Cologuard’s strong performance during 2016 reflects the accelerating demand for our non-invasive colon cancer screening test and positions us well for long-term, sustainable growth,” said Kevin Conroy, chairman and CEO of Exact Sciences. “Our annual revenue met the high end of our original expectations for 2016.”
More than 9,500 health care providers ordered Cologuard for the first time during the fourth quarter of 2016. The number of providers who have ordered Cologuard since it was launched grew to nearly 60,000 during 2016, an increase of 123 percent from the end of 2015. Read the full release here.
;
